Clinical Trial

Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors

Name: Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors — clinical trial record (NCT07505069)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

RT01-89Zr is a TF-targeting radiopharmaceutical diagnostic agent. This trial aims to evaluate the safety, biodistribution, dosimetry, and imaging characteristics of RT01-89Zr as a PET/CT tracer in patients with malignant solid tumors that highly express the TF target.

Trial Details

NCT Number	NCT07505069
Lead Sponsor	Nanolattix Biotechnology Co., Ltd.
Conditions	Solid Tumors
Enrollment	10 participants
Start Date	2026-01-29
Primary Completion	2026-12-30 (estimated)
Study Completion	2027-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-04-01